{"entity":{"type":"insider","cik":"0001615840","url":"/insider/0001615840","json_url":"/insider/0001615840.json","name":"O'Loughlin Steve","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":3,"n_filings":3,"first":"2017-06-15","last":"2018-12-10","span_basis":"filed_date"},"name_variants":[{"name":"O'Loughlin Steve","source":"filing","n_filings":3,"first_seen":"2017-06-15","last_seen":"2018-12-10"}],"transactions":[{"id":6143622,"accession":"0001213900-18-017143","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-18-017143","line_url":"/filing/0001213900-18-017143#line-1","is_derivative":false,"issuer_cik":"0001388320","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001388320","owner_cik":"0001615840","owner_name":"O'Loughlin Steve","owner_url":"/insider/0001615840","role":"Officer (Principal Financial Officer)","officer_title":"Principal Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.435,"price_display":"0.44","price_state":"stated","total_value":4350.0,"total_display":"4,350.00","shares_owned_after":35500.0,"shares_owned_after_display":"35,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-10","filed_date":"2018-12-10","scope":"insider"},{"id":6143579,"accession":"0001213900-18-007754","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-18-007754","line_url":"/filing/0001213900-18-007754#line-1","is_derivative":false,"issuer_cik":"0001388320","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001388320","owner_cik":"0001615840","owner_name":"O'Loughlin Steve","owner_url":"/insider/0001615840","role":"Officer (Principal Financial Officer)","officer_title":"Principal Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":6000.0,"total_display":"6,000.00","shares_owned_after":25500.0,"shares_owned_after_display":"25,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-15","filed_date":"2018-06-15","scope":"insider"},{"id":5358962,"accession":"0001213900-17-006527","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-17-006527","line_url":"/filing/0001213900-17-006527#line-1","is_derivative":false,"issuer_cik":"0001388320","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001388320","owner_cik":"0001615840","owner_name":"O'Loughlin Steve","owner_url":"/insider/0001615840","role":"Officer (Principal Financial Officer)","officer_title":"Principal Financial Officer","security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3500.0,"shares_display":"3,500","price_per_share":1.17,"price_display":"1.17","price_state":"stated","total_value":4095.0,"total_display":"4,095.00","shares_owned_after":3500.0,"shares_owned_after_display":"3,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-15","filed_date":"2017-06-15","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":3,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":3},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001388320","name":"Actinium Pharmaceuticals, Inc.","url":"/issuer/0001388320","role":"Officer (Principal Financial Officer)","n_filings":3,"first_seen":"2017-06-15","last_seen":"2018-12-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001615840","retrieved_at":"2026-08-21T20:08:04+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}